Oncolytics Biotech received written FDA feedback on the design of a potential pivotal Part B expansion of REO 033.
The proposed strategy could use objective response rate and duration of response toward potential accelerated approval, while progression-free survival could support full approval.
Important development for the pelareorep story.
News: https://finance.yahoo.com/healthcare/articles...00976.html
Communicated Disclaimer: https://stockresearchtoday.com/oncy/
#ONCY #Biotech #Cancer